Pharmaceutical services firm Hvivo, formerly known as Open Orphan, has unveiled plans to expand its facility in response to a rising order book. The company, which focuses on advancing research in infectious and respiratory diseases, will open a larger facility in Canary Wharf, London. The expansion is being largely funded by one of Hvivo’s clients, who is looking to accelerate their studies. The new facility will enable Hvivo to conduct more challenge trials simultaneously, with features including quarantine bedrooms, advanced laboratories, an outpatient unit, and corporate offices. The facility will also increase sample throughput and capacity to work with a broader range of pathogens. The existing clinics in Whitechapel and Queen Mary Bioenterprises Centre will remain open until the new facility is completed. The first phase of the facility is expected to be completed in the first quarter of next year, with full operational capacity by the second quarter. By consolidating its operations into a single location, Hvivo aims to improve operational efficiencies and enhance profit margins. The facility is designed to accommodate up to 70 quarantine beds and will enable the company to generate higher revenues and maintain a higher level of capacity throughout the year.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
